Study finds little difference between AMD drugs

A reduction in the frequency of retreatment, a measure that might represent significant cost savings, resulted in a small loss of efficacy irrespective of drug during the study. The findings suggested that the cheaper drug, Avastin, currently not licensed for use in AMD treatment, might be a viable alternative to Lucentis which is licensed.The study went onto say that “the choice of anti-VEGF treatment strategy is less straightforward than previously thought”.

Send this to a friend